Cordis Demonstrates Commitment to Advancing Therapies for Below-the-Knee Vascular Disease

Launches SLEEK® OTW Catheter, a new .014 Over-the-Wire PTA Catheter

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cordis Corporation is pleased to announce the launch of SLEEK® OTW Catheter, a new .014” Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter designed to help physicians save limbs and enhance patients’ lives. This new PTA Balloon was first launched at LINC (Leipzig Interventional Course, Leipzig, Germany) and ISET (International Symposium on Endovascular Therapy, Miami, Florida) earlier this year.

Lower limb amputation is a last resort for many patients with end-stage peripheral arterial disease (PAD), also known as critical limb ischemia. It is estimated that as many as 160,000 lower limbs are amputated every year in the U.S. and 60-70 percent of these amputations are performed as the first-line therapy. These lower-limb amputations come with a mortality rate of as much as 70% at five years.1 Cordis Corporation’s SLEEK® OTW Catheter is the latest technology designed to restore blood flow to the lower limbs, which helps physicians save limbs and enhance patients’ lives.

The SLEEK® OTW Catheter has a unique balance of excellent pushability with a small crossing profile that helps physicians reach small arteries below-the-knee and into the foot to restore blood flow to the lower limb. A broad portfolio of sizes is also offered with PTA balloon diameters of 1.25mm to 5.0mm and lengths up to 220mm that allow physicians to treat diffuse disease with fewer inflations. With the SLEEK® OTW Catheter, physicians can treat complex below-the-knee disease with confidence.

“The SLEEK® OTW Catheter offers our most advanced technology designed to treat challenging below the knee disease,” said Campbell Rogers, MD, Chief Scientific Officer, Global Head R&D. “This addition to our Lower Extremity product portfolio underscores our commitment to providing solutions that help save limbs and improve the quality of life for patients with advanced peripheral vascular disease.”

About Cordis Endovascular

Cordis offers a full line of Lower Extremity Solutions providing the broadest range of access, crossing and interventional products designed to help doctors save limbs and enhance patients’ lives. These solutions include: the SLEEK® OTW Catheter, the OUTBACK® LTD® Re-Entry Catheter and our landmark S.M.A.R.T.® CONTROL® Iliac Stent System.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with cardiac and vascular interventionalists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com



CONTACT:

Cordis Corporation
Media:
Sandy Pound
908-541-4040 Office
908-432-2829 Mobile
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Cardiology  Medical Devices  Pharmaceutical  Diabetes

MEDIA:

Logo
 Logo

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.